BioLASCO Taiwan Past Earnings Performance
Past criteria checks 1/6
BioLASCO Taiwan's earnings have been declining at an average annual rate of -6.6%, while the Life Sciences industry saw earnings growing at 20.8% annually. Revenues have been declining at an average rate of 5.1% per year. BioLASCO Taiwan's return on equity is 9.6%, and it has net margins of 14.6%.
Key information
-6.6%
Earnings growth rate
-7.0%
EPS growth rate
| Life Sciences Industry Growth | 5.5% |
| Revenue growth rate | -5.1% |
| Return on equity | 9.6% |
| Net Margin | 14.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think You Should Be Aware Of Some Concerning Factors In BioLASCO Taiwan's (GTSM:6662) Earnings
Apr 01
Are BioLASCO Taiwan Co., Ltd.'s (GTSM:6662) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Mar 11Investors In BioLASCO Taiwan Co., Ltd. (GTSM:6662) Should Consider This, First
Feb 10
Is BioLASCO Taiwan (GTSM:6662) A Risky Investment?
Jan 08BioLASCO Taiwan Co., Ltd.'s (GTSM:6662) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Dec 10Revenue & Expenses Breakdown
How BioLASCO Taiwan makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 291 | 43 | 56 | 0 |
| 30 Jun 24 | 282 | 42 | 54 | 0 |
| 31 Mar 24 | 263 | 46 | 54 | 0 |
| 31 Dec 23 | 265 | 50 | 54 | 0 |
| 30 Sep 23 | 252 | 44 | 54 | 0 |
| 30 Jun 23 | 252 | 45 | 55 | 0 |
| 31 Mar 23 | 235 | 42 | 55 | 0 |
| 31 Dec 22 | 236 | 42 | 55 | 0 |
| 30 Sep 22 | 225 | 43 | 53 | 0 |
| 30 Jun 22 | 225 | 45 | 52 | 0 |
| 31 Mar 22 | 229 | 45 | 52 | 0 |
| 31 Dec 21 | 228 | 45 | 51 | 0 |
| 30 Sep 21 | 254 | 52 | 51 | 0 |
| 30 Jun 21 | 259 | 52 | 51 | 0 |
| 31 Mar 21 | 257 | 52 | 50 | 0 |
| 31 Dec 20 | 299 | 63 | 53 | 0 |
| 30 Sep 20 | 277 | 52 | 55 | 0 |
| 30 Jun 20 | 273 | 50 | 52 | 0 |
| 31 Mar 20 | 356 | 69 | 55 | 0 |
| 31 Dec 19 | 347 | 55 | 55 | 0 |
| 30 Sep 19 | 355 | 53 | 63 | 0 |
| 30 Jun 19 | 406 | 68 | 63 | 0 |
| 31 Mar 19 | 323 | 48 | 58 | 0 |
| 31 Dec 18 | 294 | 53 | 54 | 0 |
| 30 Sep 18 | 389 | 72 | 53 | 0 |
| 30 Jun 18 | 333 | 55 | 52 | 0 |
| 31 Mar 18 | 327 | 53 | 52 | 0 |
| 31 Dec 17 | 326 | 53 | 51 | 0 |
| 30 Sep 17 | 225 | 37 | 45 | 0 |
| 30 Jun 17 | 234 | 38 | 47 | 0 |
| 31 Mar 17 | 233 | 39 | 45 | 0 |
| 31 Dec 16 | 232 | 40 | 44 | 0 |
| 31 Dec 15 | 226 | 40 | 44 | 0 |
| 31 Dec 14 | 227 | 45 | 41 | 0 |
Quality Earnings: 6662 has high quality earnings.
Growing Profit Margin: 6662's current net profit margins (14.6%) are lower than last year (17.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6662's earnings have declined by 6.6% per year over the past 5 years.
Accelerating Growth: 6662's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6662 had negative earnings growth (-4.5%) over the past year, making it difficult to compare to the Life Sciences industry average (-5.2%).
Return on Equity
High ROE: 6662's Return on Equity (9.6%) is considered low.